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Abstract
The accurate diagnosis of acute kidney injury (AKI) is especially
problematic in critically ill patients in whom renal function is in an
unsteady state, rendering creatinine-based baseline assessment
measures of renal function potentially inadequate. Herrero-Morin
and colleagues performed a cross-sectional analysis of the ability
of cystatin C and β2 microglobulin to reflect creatinine clearance in
pediatric patients with AKI. The aim of this commentary is to review
the current state of AKI clinical and translational research in the
light of the results presented in that study.
Current standard assessments of renal function for pediatric
patients use serum creatinine or formulas based on serum
creatinine designed for longitudinal assessment of baseline
renal function. The accurate diagnosis of acute kidney injury
(AKI) is especially problematic in critically ill patients in whom
renal function is in an unsteady state, thus rendering such
creatinine-based baseline assessment measures of renal
function potentially inadequate. Pediatric patients comprise a
valuable cohort for study, because they usually do not carry
many of the co-morbidities that often confound adult patient
studies. In this issue of Critical Care, Herrero-Morin and
colleagues assess the ability of two markers, cystatin C and
β2 microglobulin (β2M), to detect decreases in renal function
accurately in 25 critically ill children [1].
The authors conducted a careful study to obtain 24-hour
urine collections of creatinine clearance before obtaining serum
β2M and cystatin C samples. Fourteen (56%) developed AKI,
which they defined as a creatinine clearance of less than
80 ml/min per 1.73 m2. Their primary results demonstrated
thresholds for both β2M (1.5 mg/l) and cystatin C (0.6 mg/l)
that exhibited reasonable sensitivity and specificity to detect
AKI accurately, whereas serum creatinine was no different
between patients with and without AKI. The present study is
therefore the first report of non-creatinine-based methods to
estimate renal function in critically ill pediatric patients with
AKI.
The rationale for assessing AKI markers in critically ill patients
is strong. Numerous studies demonstrate that AKI is an
independent risk factor for mortality, so critically ill patients
are dying from and not just ‘with’ AKI. Until recently, pediatric
AKI studies used the Schwartz formula [2], a creatinine-
based equation designed to assess baseline renal function
[3]. The need for accurate and sensitive description of AKI
has led to the development of a multidimensional AKI classifi-
cation system, which in essence grades AKI severity. The
most widely referenced system is the RIFLE (Risk, Injury,
Failure, Loss, End-stage kidney disease) criteria, proposed as
an empiric system by the Acute Dialysis Quality Initiative [4].
Hoste and colleagues validated the RIFLE criteria in critically
ill adult patients, finding that patients with maximum RIFLE
class R, class I and class F had hospital mortality rates of
8.8%, 11.4% and 26.3%, respectively [5]. Our center recently
reported similar results for pediatric modified RIFLE criteria in
a pediatric cohort of critically ill children: AKI by pediatric
RIFLE during admission was an independent predictor of
intensive care, hospital length of stay and an increased risk of
death independent of the Pediatric Risk of Mortality (PRISM
II) score (odds ratio 3.0) [6].
Early recognition of AKI, before changes in serum creatinine
occur, has been an area of intensive investigation over the
past 5 years. The rationale for such research emanates from
studies demonstrating that even small increases in serum
creatinine are associated with increases in patient morbidity
and mortality. Chertow found a 6.5-fold increase in the odds
of death for patients with a 0.5 mg/dl increase in serum
creatinine, even when adjusted for numerous co-morbidities
[7]. We have found a sevenfold increase in the odds of death in
Commentary
Kidney function assessment in the critically ill child: is it time to
leave creatinine behind?
Stuart L Goldstein
Texas Children’s Hospital, 6621 Fannin Street, MC 3-2482, Houston, TX 77030, USA
Corresponding author: Stuart L Goldstein, stuartg@bcm.edu
Published: 15 June 2007 Critical Care 2007, 11:141 (doi:10.1186/cc5935)
This article is online at http://ccforum.com/content/11/3/141
© 2007 BioMed Central Ltd
See related research by Herrero-Morin et al., http://ccforum.com/content/11/3/R59
AKI = acute kidney injury; β2M = β2 microglobulin; GFR = glomerular filtration rate; RIFLE = Risk, Injury, Failure, Loss, End-stage kidney disease.Page 2 of 2
(page number not for citation purposes)
Critical Care    Vol 11 No 3 Goldstein
pediatric patients with acute decompensated heart failure who
had an serum creatinine increase of 0.3 mg/dl or more [8].
Cystatin C is a logical marker for AKI study because its
concentration is not affected by muscle mass and it is not
secreted by the renal tubule; it is therefore a potentially more
accurate and earlier marker of change in glomerular filtration
rate (GFR) than serum creatinine. Herget-Rosenthal and
colleagues found increases in serum cystatin C 1½ days
before AKI development (defined as attaining RIFLE-R [9]),
and the same group found serum cystatin C to detect
decreased GFR 1½ days before serum creatinine increased
in patients undergoing unilateral nephrectomy for kidney
donation [10]. Because both cystatin C and β2M in the
current study by Herrero-Morin differed between patients
with and without AKI, whereas serum creatinine did not differ,
a reasonable inference could be that serum β2M and cystatin
C detect renal injury before changes in serum creatinine.
However, the present study was not designed to assess for
earlier AKI recognition. Further study of these two markers,
along with potential urinary AKI biomarkers currently under
investigation, including NGAL (neutrophil gelatinase-associated
lipocalin) [11], interleukin-18 [12] and KIM-1 (kidney injury
molecule-1) [13], is required in pediatric patients to develop a
panel of markers for the accurate and reliable assessment of
early AKI development, AKI duration and site of injury. So, is it
time to leave serum creatinine behind as a marker of renal
function in patients with AKI? Currently, the answer is no, but
the work of Herrero-Morin and colleagues argues strongly for
the study of other markers, including cystatin C and β2M, in
the near future.
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